argenex (ARGX) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of argenex (NASDAQ: ARGX) recently:

• 1/31/2026 – argenex was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 1/22/2026 – argenex was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
• 1/21/2026 – argenex had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 1/20/2026 – argenex had its price target raised by analysts at Wells Fargo & Company from $1,264.00 to $1,317.00. They now have an “overweight” rating on the stock.
• 1/14/2026 – argenex had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $1,000.00 price target on the stock.
• 1/10/2026 – argenex was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 1/8/2026 – argenex had its price target lowered by analysts at Citigroup Inc. from $1,124.00 to $1,091.00. They now have a “buy” rating on the stock.
• 1/8/2026 – argenex had its price target raised by analysts at Truist Financial Corporation from $950.00 to $1,030.00. They now have a “buy” rating on the stock.
• 12/19/2025 – argenex was upgraded by analysts at DZ Bank AG to a “strong-buy” rating.
• 12/18/2025 – argenex was downgraded by analysts at Robert W. Baird from a “strong-buy” rating to a “hold” rating.
• 12/18/2025 – argenex had its “neutral” rating reaffirmed by analysts at Robert W. Baird. They now have a $858.00 price target on the stock, down previously from $924.00.
• 12/17/2025 – argenex had its price target raised by analysts at Royal Bank Of Canada from $860.00 to $925.00. They now have an “outperform” rating on the stock.
• 12/11/2025 – argenex had its price target raised by analysts at Wells Fargo & Company from $1,095.00 to $1,316.00. They now have an “overweight” rating on the stock.
• 12/11/2025 – argenex had its price target raised by analysts at Stifel Nicolaus from $1,028.00 to $1,248.00. They now have a “buy” rating on the stock.
• 12/8/2025 – argenex had its price target raised by analysts at JPMorgan Chase & Co. from $925.00 to $1,100.00. They now have an “overweight” rating on the stock.

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.